The changing face of HIV/AIDS in treated patients

Current HIV Research

Volumn 7, Issue 4, 2009, Pages 365-377

  Llibre, Josep M ^a   Falco, Vicenç ^b   Tural, Cristina ^a   Negredo, Eugenia ^a   Pineda, Juan A ^c   Muñoz, Jose ^a   Ortega, Enrique ^d   Videla, Sebastia ^a   Sirera, Guillem ^a   Martinez, Esteban ^e   Miralles, Celia ^f   Iribarren, Josean ^g   Galindo, Maria J ^h   Domingo, Pere ⁱ   D'Arminio Monforte, Antonella ^j   Miro, Jose M ^e   Clotet, Bonaventura ^a,k  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f HOSPITAL XERAL CALDE   (Spain)

^g HOSPITAL DONOSTIA   (Spain)

^h HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

ⁱ Hospital Sant Pau   (Spain)

^j UNIVERSITY OF MILAN   (Italy)

^k IrsiCaixa Foundation   (Spain)

more..

Author keywords

AIDS; AIDS dementia complex; Cardiovascular disease; Hepatitis; Immune reconstitution syndrome; Neoplasia; Papillomavirus; Progressive multifocal leukoencephalopathy

Indexed keywords

ADEFOVIR; ALBINTERFERON ALPHA2B; ALPHA INTERFERON; BCG VACCINE; CD4 ANTIGEN; CIDOFOVIR; CLEVUDINE; CYTARABINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ENTECAVIR; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; ISONIAZID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PEGINTERFERON; PRADEFOVIR; RIBAVIRIN; RIFAMPICIN; STAVUDINE; TELAPREVIR; TELBIVUDINE; TENOFOVIR; TUBERCULIN; UNINDEXED DRUG; VALOPICITABINE; VALTORCITABINE; WART VIRUS VACCINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BONE DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONDOM; DEMENTIA; DISEASE ASSOCIATION; EARLY DIAGNOSIS; HEMATOLOGIC DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; JC VIRUS; KAPOSI SARCOMA; KIDNEY DISEASE; LIPOATROPHY; MALIGNANT NEOPLASTIC DISEASE; MYCOBACTERIUM TUBERCULOSIS; NEUROLOGIC DISEASE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; PAPANICOLAOU TEST; PAPILLOMA VIRUS; PATIENT CARE; POLYMERASE CHAIN REACTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RISK MANAGEMENT; T CELL DEPLETION; TUBERCULIN TEST; TUBERCULOSIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; AIDS RELATED COMPLEX; B CELL LYMPHOMA; CARDIOVASCULAR DISEASE; METHODOLOGY; NEOPLASM;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED COMPLEX; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LYMPHOMA, AIDS-RELATED; NEOPLASMS;

EID: 69849111709     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016209788680633     Document Type: Review

References (187)

1. Cascade Collaboration. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006; 20: 741-749
2. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293-299
3. Ewing FM, Bhaskaran K, McLean K, et al. Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS 2008; 22: 89-95. (Pubitemid 350294882)
4. Lohse N, Hansen AE, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146: 87-95.
5. The Data Collection on Adverse Events of Anti-HIV Drugs (D: A: D) Study Group. Writing committee: d'Arminio Monforte A, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22: 2143-2153
6. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ Count-Guided Interruption of Antiretroviral Treatment. New Engl J Med 2006; 355: 2283-2296
7. th Conference on Retrovirus and Opportunistic Infections (Los Angeles), 2007.
8. th Conference on Retrovirus and Opportunistic Infections (Los Angeles), 2007.
9. Falco V, Olmo M, Villar del Saz S, et al. Influence of HAART on the clinical course of HIV-1 infected patients with Progressive Multifocal Leukoencephalopathy. Results of an observational multicenter study. J Acquir Immune Def Syndr 2008; 49(1): 26-31.
10. Mussini C, Manzardo C, Johnson M, et al. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS 2008; 22: 2461-2469
11. Manzardo C, Zaccarelli M, Agüero F, Antinori A, Miró JM. Optimal timing and best antiretroviral regimen in treatment-naive HIVinfected individuals with advanced disease. J Acquir Immune Defic Syndr 2007; 46(Suppl 1): S9-18. (Pubitemid 47312321)
12. Zoloppa A, Andersen J, Komarow L, et al. Immediate vs Deferred ART in the Setting of Acute AIDS-related Opportunistic Infection: Final Results of a Randomized Strategy Trial, ACTG A5164. Abstract 142. In program and Abstracts: 15 TH Conference on Retroviruses and Opportunistic Infections. Boston: MA, February 3-6, 2008..
13. th Conference on Retrovirus and Opportunistic Infections (Los Angeles), 2007.
14. Martinez JV, Mazziotti JV, Efron ED, et al. Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology 2006; 67: 1692-1694
15. Silva MTT, Pacheco MCN, Vaz B. Inflammatory progressive multifocal leukoencephalopathy alter antiretroviral treatment. AIDS 2006; 20: 469-471
16. Vendrely A, Bienvenu B, Gasnault J, Thiebault JB, Salmon D, Gray F. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol (Berl) 2005; 109: 449-455 (Pubitemid 40637320)
17. Di Giambenedetto S, Vago G, Pompucci A, et al. Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity? Neurology 2004; 63: 2452-2453
18. Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?. Ann Neurol 2006; 60: 162-173
19. Koralnik IJ. New insights into progressive multifocal leukoencephalopathy. Curr Opin Neuro 2004 ; 17: 365-370 (Pubitemid 38720991)
20. Marzocchetti A, Di Giambenedetto S, Cingolani A, Ammassari A, Cauda R, De Lyca A. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 2005; 43: 4175-4177 (Pubitemid 41129718)
21. Cinque P, Koralnik IJ, Clifford DB. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol 2003; 9(Suppl1): 88-92. (Pubitemid 36656477)
22. Du Pasquier RA, Autissier P, Zheng Y, Jean-Jacques J, Koralnik IJ. Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies. AIDS 2005; 19: 2069-2076 (Pubitemid 41668994)
23. th Conference on Retrovirus and Opportunistic Infections (Los Angeles), 2007.
24. Bossolasco S, Calori G, Moretti F, et al. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIVassociated progressive multifocal leukoencephalopathy. Clin Infect Dis 2005; 40: 738-744 (Pubitemid 40381351)
25. Berenguer J, Miralles P, Arrizabalaga J, et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2003; 36: 1047-1152 (Pubitemid 36513291)
26. Antinori A, Cingolani A, Lorenzini P, et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003; 9(Suppl 1): 47-53. (Pubitemid 36656471)
27. Patel P, Hanson D, Sullivan P, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Annals Intern Med 2008; 148: 728-736
28. National Cancer Institute: SEER Cancer Statistic Review, 1975-2002. Bethesda, MD: National Cancer Institute 2005.
29. Friis-Møller N, Weber R, Reiss P, et al: Combination antiretroviral therapy and the risk of miocardial infarction. N Engl J Med 2003; 349: 1993-2003.
30. Olsen CH, Friis-Møller N, d'Arminio Monforte A, for the CoDe Working Group: Pilot of the CoDe (Coding of Death) project - a standardized approach to code causes of death in HIV infected individuals. 10th European AIDS Conference/EACS, Dublin, Nov 2005.
31. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency viruses (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34: 121-130 (Pubitemid 40347381)
32. The D: A: D Study. Writing Committee: Weber R, Sabin C, Friis-Moller N, et al. Liver-related deaths in persons infected with the human Immunodeficiency Virus. Arch Intern Med 2006; 166: 1632-1641
33. Murillas J, Del Rio M, Riera M, et al. Increased incidence of hepatocellular carcinoma (HCC) in HIV-1 infected patients. Eur J Intern Med 2005; 16: 113-115 (Pubitemid 40523054)
34. Engels EA, Goedert JJ. Human immunodeficiency virus/acquired immunodeficiency syndrome and cancer: past, present, and future. J Natl Cancer Inst 2005; 97: 407-409 (Pubitemid 40528595)
35. Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005; 104: 1505-1511 (Pubitemid 41356166)
36. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285: 1736-1745 (Pubitemid 32259908)
37. D'Souza G, Wiley DJ, Li X, et al. incidence and epidemiology of anal cancer in the multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2008; 48: 491-499
38. Mitsuyasu R. Non-AIDS Defining Malignancies in HIV. Topics HIV Med 2008; 16(4): 117-121
39. Serraino D, Dal Maso L, La Vecchia C, et al. Invasive cervical cancer as an AIDS-defining illness in Europe. AIDS 2002; 16: 781-786 (Pubitemid 34274469)
40. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus types associated with cervical cancer. J Pathol 1999; 189: 12-19
41. Muñoz N, Bosch FX, De Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 384: 518-527 (Pubitemid 36159887)
42. Palefsky J. Human papillomavirus and anal neoplasia. Curr HIV/AIDS Rep 2008; 5: 78-85.
43. Uronis HE, Bendell JC. Anal cancer: an overview. Oncologist 2007; 12: 524-534
44. Psyrri A, DiMaio D. Human papillomavirus in cervical and headand-neck cancer. Nat Clin Pract Oncol 2008; 5: 24-31.
45. Sirera G, Videla S, Romeu J, et al. Fatal fast-evolution of nasopharyngeal squamous cell carcinoma in an HIV patient with EBV and HPV (-16 AND -33) in blood serum. Open AIDS J 2008; 2: 8-9.
46. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
47. Weller SC, Stanberry LR. Estimating the population prevalence of HPV. JAMA 2007; 297; 876-878
48. Kojic EM, Cu-Uvin S. Update: human papillomavirus infection remains highly prevalent and persistent among HIV-infected individuals. Curr Opin Oncol 2007; 19: 464-469 (Pubitemid 47356603)
49. Sirera G, Videla S, Cañadas MP, et al. High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV positive men. AIDS 2006; 20: 1201-1204 (Pubitemid 43786111)
50. Videla S, Darwich L, Cañadas MP, et al. Epidemiological data of different human papillomavirus genotypes in cervical specimens of HIV-1-infected women without history of cervical pathology. JAIDS 2008; (in press).
51. Palefsky J. Human Papillomavirus infection in HIV-infected persons. Top HIV Med 2007; 15: 130-133
52. Epstein RJ. Primary prevention of human papillomavirus dependent neoplasia: No condom, no sex. Eur J Cancer 2005; 41: 2595-2600 (Pubitemid 41607550)
53. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study. Arch Intern Med 2006; 166: 1632-1641 (Pubitemid 44232373)
54. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34. (Pubitemid 44306484)
55. Shire NJ, Welge JA, Sherman KE. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. J Viral Hepat 2007; 14: 239-248
56. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086-1097
57. Sethi A, Shiffman ML. Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response. Infect Dis Clin North Am 2006; 20: 115-135 (Pubitemid 43343737)
58. Fuster D, Huertas JA, Gomez G, et al; PEG-TOX Research Group. Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy. Antivir Ther 2005; 10: 841-847
59. Muir AJ, McHutchison JG. Growth factors during HCV therapy may be "cost-effective", but are they "effective"? Hepatology 2006; 44: 1400-1403
60. Bräu N, Rodriguez-Torres M, Prokupek D, et al. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha- 2b+ full-course vs 16-week delayed ribavirin. Hepatology 2004; 39: 989-998
61. Behler CM, Vittinghoff E, Lin F, et al. Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects. Clin Infect Dis 2007; 44: 1375-1383 (Pubitemid 46717302)
62. Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 2006; 44: 1598-1606
63. Hornberger J, Torriani FJ, Dieterich DT, et al. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. J Clin Virol 2006; 36: 283-291 (Pubitemid 44066896)
64. Gish RG, Arora S, Rajender Reddy K, et al. Virological response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol 2007; 47: 51-59 (Pubitemid 46817694)
65. Hezode C, Ferenci P, Dusheiko GM, et al. PROVE 2: Phase II study of VX950 (Telaprevir) in combination with peginterferon alfa 2 a with or without ribavirin in subjects with chronic hepatitis C, first interim analysis. Hepatology 2007; 46(suppl): Abstract 80.
66. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha- 2b for genotype 1 nonresponders. Gastroenterology 2007; 132: 1270-1278 (Pubitemid 46627577)
67. Pockros PJ, Nelson D, Godofsky E, et al. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008; 48: 385-397
68. Dienstag JL. Hepatitis B Virus Infection. New Engl J Med 2008; 359: 1486-1500
69. Gatanaga H, Yasuoka A, Kikuchi Y, Tachikawa N, Oka S. Influence of prior HIV-1 infection on the development of chronic hepatitis B infection. Eur J Clin Microbiol Infect Dis 2000; 19: 237-239 (Pubitemid 30201305)
70. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-1926.
71. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73. (Pubitemid 43042691)
72. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1-139. Available at http: //www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf [Accessed November 5, 2008].
73. European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. October 2008. Available at: http: //www.eacs.eu/. Accessed November 18, 2008.
74. McMahon M, Jilek B, Brennan T, et al. The anti-hepatitis B drug entecavir inhibits HIV-1 replication and selects HIV-1 variants resistant to antiretroviral drugs. Abstract 136LB. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA. February 2007.
75. Sheldon J, Corral A, Rodes B, et al. Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS 2005; 19: 2036-2038 (Pubitemid 41669031)
76. Zoulim F. Antiviral therapy of chronic hepatitis B; can we clear the virus and prevent drug resistence?. Antivir Chem Chemother 2004; 15: 299-305. (Pubitemid 39656966)
77. Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004: 9: 679-693 (Pubitemid 39434331)
78. Brunelle MN, Jacquard AC, Pichouds C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 1391-1399
79. Ristig M, Drechudiesler H, Powderly WG. Hepatic steatosis and HIV infection. AIDS Patient Care STDS 2005; 19: 356-365
80. th Conference on Retrovirus and Opportunistic Infections. Los Angeles (USA). February, 2007. Abstract 822.
81. Moreno-Torres A, Domingo P, Pujol J, Blanco-Vaca F, Arroyo JA, Sambeat MA. Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy. Antivir Ther 2007; 12: 195-203. (Pubitemid 46569905)
82. Hadigan C, Liebau J, Andersen R, Holalkere NS, Sahani VD. Magnetic resonance spectroscopy of hepatic lipid content and associated risk factors in HIV infection. J Acquir Immune Defic Syndr 2007; 46: 312-317 (Pubitemid 350287358)
83. Sterling RK, Contos MJ, Smith PG, et al. Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2008; 47: 1118-1127
84. Rodríguez-Torres M, Govindarajan S, Solá R, et al. Hepatic steatosis in HIV/HCV co-infected patients: Correlates, efficacy and outcomes of anti-HCV therapy: A paired liver biopsy study. J Hepatol 2008; 48: 756-764
85. Caro-Murillo AM, Castilla J, Perez-Hoyos S, et al. Spanish cohort of naive HIV-infected patients (CoRIS): rationale, organization and initial results. Enferm Infecc Microbiol Clin 2007; 25: 23-31. (Pubitemid 46232687)
86. Anderson SR, Maguire H, Carless J. Tuberculosis in London: a decade and a half of no decline in tuberculosis epidemiology and control. Thorax 2007; 62: 162-167 (Pubitemid 46271723)
87. Moreno S, Jarrin I, Iribarren JA, et al. Impact of HAART on the incidence of TB among HIV-infected patients [Abstract 847]. 14th Conference on Retrovirus and Opportunistic Infections, Los Angeles, Ca, US. February 25-28, 2007.
88. Girardi E, Sabin CA, D'Arminio MA, et al. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005; 41: 1772-1782 (Pubitemid 41759864)
89. Bonnet MM, Pinoges LL, Varaine FF, et al. Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden. AIDS 2006; 20: 1275-1279
90. Marston B, Miller B. Tuberculosis: the elephant in the AIDS clinic? AIDS 2006; 20: 1323-1325
91. Elzi L, Schlegel M, Weber R, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007; 44: 94-102. (Pubitemid 44968992)
92. Cobelens FG, Egwaga SM, van Ginkel T, Muwinge H, Matee MI, Borgdorff MW. Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values. Clin Infect Dis 2006; 43: 634-639 (Pubitemid 44267127)
93. Elliott J, Sarun S, Chin S, et al. Performance characteristics of a whole blood interferon gamma release assay in HIV patients commencing ART in a high TB incidence setting [Abstract 859]. 14th Conference on Retrovirus and Opportunistic Infections, Los Angeles, Ca, US. February 25-28, 2007.
94. Luetkemeyer A, Charlebois ED, Flores L, et al. Comparison of an interferon gamma release assay to conventional tuberculin skin testing for the diagnosis of latent TB infection in HIV-infected individuals in San Francisco [Abstract 860]. 14th Conference on Retrovirus and Opportunistic Infections, Los Angeles, Ca, US. February 25-28, 2007.
95. Lawn SD, Bangani N, Wilkinson RJ, et al. Utility of the ELIspot assay in the diagnosis of latent Mycobacterium tuberculosis infection among HIV-infected patients with advanced immunodeficiency in South Africa [Abstract 861]. 14th Conference on Retrovirus and Opportunistic Infections, Los Angeles, Ca, US. February 25-28, 2007.
96. French AL, Evans CT, Anastos K, et al. Incidence of tuberculin skin test conversion among HIV-infected and -uninfected women: results of a 6-year study. J Acquir Immune Defic Syndr 2006; 42: 592-596 (Pubitemid 44162429)
97. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43: 42-46 (Pubitemid 44306486)
98. Schiffer JT, Sterling TR. Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr 2007; 44: 229-234
99. Moreno S, Hernandez B, Dronda F. Antiretroviral therapy in AIDS patients with tuberculosis. AIDS Rev 2006; 8: 115-124 (Pubitemid 44614029)
100. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21: 335-341 (Pubitemid 46175045)
101. Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, et al. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen. J Antimicrob Chemother 2006; 58: 1017-1023
102. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect 2006; 53: 357-363 (Pubitemid 44688983)
103. Manosuthi W, Ruxrungtham K, Likanonsakul S, et al. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis 2007; 44: 141-144 (Pubitemid 44969000)
104. Srikantiah P, Walusimbi M, Kayanja H, et al. Safety and early virologic response of zidovudine + lamivudine + abacavir for patients co-infected with HIV and TB in Uganda [Abstract 855]. 14th Conference on Retrovirus and Opportunistic Infections, Los Angeles, Ca, US. February 25-28, 2007.
105. Centers for Disease Control and Prevention. Revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 2006; 55: 1176.
106. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580 (Pubitemid 44780738)
107. Weyer K. Transmission of extensively drug-resistant TB in South Africa and implications for infection control in health care settings [Abstract 8]. 14th Conference on Retrovirus and Opportunistic Infections, Los Angeles, Ca, US. February 25-28, 2007.
108. Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martín-Casabona N. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13: 380-387 (Pubitemid 46348124)
109. Migliori GB, Ortmann J, Girardi E, et al. Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis 2007; 13: 781-782 (Pubitemid 46698749)
110. Manissero D, Fernandez dlH. Surveillance methods and case definition for extensively drug resistant TB (XDR-TB) and relevance to Europe: summary update. Euro Surveill 2006; 11: E061103.
111. Caws M, Thwaites G, Stepniewska K, et al. Beijing genotype of Mycobacterium tuberculosis is significantly associated with human immunodeficiency virus infection and multidrug resistance in cases of tuberculous meningitis. J Clin Microbiol 2006; 44: 3934-3939 (Pubitemid 44737232)
112. Dilley JW, Schwartz S, Loeb L, Hsu L, Nelson K, Scheer S. The decline of incident cases of HIV-associated neurological disorders in San Francisco, 1991-2003. AIDS 2005; 19: 634-635
113. Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990- 1998. Neurology 2001; 56: 257-260
114. Neuenburg JK, Brodt HR, Herndier BG, et al. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31: 171-177
115. McArthur JC, Haughey N, Gartner S, et al. Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol 2003; 9: 205-221 (Pubitemid 36656454)
116. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 1993; 43: 2245-2252 (Pubitemid 23346956)
117. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002; 8: 136-142 (Pubitemid 34520894)
118. Cysique LA, Brew BJ, Halman M, et al. Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapytreated patients. J Acquir Immune Defic Syndr 2005; 39: 426-429 (Pubitemid 41003788)
119. Muñoz-Moreno JA. Neurocognitive and Motor Disorders in HIV Infection. Assessment and Interventions. In: Valerie N. Plishe, editor. Research Focus on Cognitive Disorders. Hauppauge, New York: Nova Science Publishers, Inc 2007.
120. Tozzi V, Balestra P, Salvatori M, et al. Factors associated with persistent neurocognitive impairment despite long-term HAART in patients with HIV dementia [Abstract 354]. 13th Conference on Retroviruses & Opportunistic Infections. Denver, CO, USA 5-8 February 2006,.
121. Muñoz-Moreno JA, Fumaz CR, Prats A, et al. Recommended Earlier Initiation of ART Based on Nadir CD4 Cell Count as a Risk Factor for HIV-related Neurocognitive Impairment [Abstract 383]. The 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA 25-28 February, 2007,
122. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20: 2165-2174
123. Overton E, Mondy K, Bush T, et al. Factors Associated with Low Bone Mineral Density in a Large Cohort of HIV-infected US Adults: Baseline Results from the SUN Study [Abstract 836]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 25-28, 2007.
124. Mondy K, Powderly WG, Claxton SA, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005; 38: 426-431 (Pubitemid 40381552)
125. Negredo E, Martínez-López E, Paredes L, et al. Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. AIDS 2005; 19: 343-345 (Pubitemid 40396568)
126. Guaraldi G, Orlando G, Madeddu G, et al. Alendronate reduces bone turnover in HIV-associated osteopenia and osteoporosis. HIV Clin Trials 2004; 5: 269-277 (Pubitemid 39545399)
127. McComsey G, Kendall M, Tebas P, et al. Alendronate with a calcium and vitamin D supplementation is superior to calcium and vitamin D alone in the management of decreased bone mineral density in HIVinfected patients: Results of ACTG 5163 [Abstract 42]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 25-28, 2007.
128. Negredo E, Martinez E, Cinquegrana D, Estany C, Clotet B. Therapeutic management of bone demineralization in the HIVinfected population. AIDS 2007; 21: 657-663 (Pubitemid 46568622)
129. Quimby D, Brito MO. Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature. AIDS Read 2005; 15: 357-364 (Pubitemid 40980486)
130. Fine DM. Editorial comment: Fanconi syndrome and tenofovir--understanding proximal tubular function. AIDS Read 2007; 17: 326-327
131. Mocroft A, Kirk O, Gatell J, et al. The EuroSIDA Study Group. Detection of chronic renal failure among HIV patients within the EuroSIDA study [Abstract 828]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 25-28, 2007.
132. Fux C, Simcock M, Wolbers M, et al. Swiss HIV Cohort Study (SHCS). Tenofovir treatment is associated with a decrease in calculated glomerular filtration rates in a large observational cohort [Abstract 834]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 25-28, 2007.
133. Moore R, Keruly J, Gallant J. Tenofovir and Renal Dysfunction in Clinical Practice [Abstract 832]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 25-28, 2007.
134. Gallant J, Pozniak A, Staszewski S, DeJesus E, Chen S, Enejosa J. Efficacy and safety of tenofovir-containing vs non-tenofovircontaining regimens in black ART-naive patients [Abstract 505]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 25-28, 2007.
135. Wai H, Katsivas T, Ballard C, Barber E, Mathews C. Risk factors for tenofovir-associated nephrotoxicity identified in an HIV clinic cohort [Abstract 833]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 25-28, 2007.
136. Goicoechea M, Liu S, Best B, et al. California Collaborative Treatment Group (CCTG) 578 Team. Increased renal impairment in patients receiving TDF+PI
137. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40: 1559-1585
138. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 2095-2106 (Pubitemid 351679596)
139. Haubrich RH, Riddler S, DiRienzo G, et al. Metabolic outcomes of ACTG 5142: a prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection [Abstract 38]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, California, February 25-28, 2007.
140. Engelson ES, Kotler DP, Tan Y, et al. Fat distribution in HIVinfected patients reporting truncal enlargement quantified by wholebody magnetic resonance imaging. Am J Clin Nutr 1999; 69: 1162-1169 (Pubitemid 29252048)
141. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58. (Pubitemid 28190689)
142. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004; 38: 263-270
143. Moyle GJ, Sabin CA, Cartledge J, et al. RAVE (Randomized Abacavir versus Viread Evaluation) Group UK. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20: 2043-2050
144. Carr A, Workman C, Smith DE, et al. Mitochondrial Toxicity (MITOX) Study Group. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288: 207-215
145. Milinkovic A, Martinez E, López S, et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 2007; 12: 407-415 (Pubitemid 46787986)
146. Madruga JR, Cassetti I, Suleiman JM, et al. The safety and efficacy of switching stavudine to tenofovir DF in combination with lamivudine and efavirenz in HIV-1-infected patients: three-year follow-up after switching therapy. HIV Clin Trials 2007; 8: 381-390 (Pubitemid 350305212)
147. Nolan D, Hammond E, James I, McKinnon E, Mallal S. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003; 8: 617-626
148. Dubé MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; 19: 1807-1808 (Pubitemid 41546599)
149. Dubé MP, Komarow L, Mulligan K, et al. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr 2007; 45: 508-514 (Pubitemid 47294922)
150. Tebas P, Zhang J, Yarasheski K, et al. Switch to a protease inhibitorcontaining/ nucleoside reverse transcriptase inhibitor-sparing regimen increases appendicular fat and serum lipid levels without affecting glucose metabolism or bone mineral density. The results of a prospective randomized trial, ACTG 5125s [Abstract 40]. In: Program and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston: MA February 22-25, 2005.
151. Murphy E, Zhang J, Hafner R, et al. Peripheral and visceral fat changes following a treatment switch to a nonthymidine analogue or nucleoside-sparing regimen in patients with peripheral lipoatrophy: 48-week final results of ACTG a5110, a prospective, randomized multicenter clinical trial [Abstract 755]. 13th CROI 2006, Denver, CO.
152. Cameron DW, da Silva B, Arribas J, et al. Significant sparing of peripheral lipoatrophy by HIV treatment with LPV/r + ZDV/3TC induction followed by LPV/r monotherapy compared with EFV + ZDV/3TC [Abstract 44]. In: Program and Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles: CA, .February 25-28, 2007.
153. Diaz-Delfin J, Gallego-Escuredo JM, Milanski M, et al. Comparison of the effects of Lopinavir/ritonavir and Efavirenz on Gene Expression and Differentiation of human adipocytes. Antiv Therapy 2008; (Suppl 4): A23.
154. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43: 535-540. (Pubitemid 44885619)
155. Hammond E, Nolan D, McKinnon E, et al. Differential effects of nucleoside reverse transcriptase inhibitor (NRTI) regimens on adipocytes mitochondrial DNA depletion in HIV-infected patients [Abstract 16]. Program and Abstracts of 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Washington:, DC, October 25-28, 2004.
156. Podzamczer D, Ferrer E, Sanchez P, et al. ABCDE (Abacavir vs d4T (stavudine) plus efavirenz) Study Team. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007; 44: 139-147
157. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir df vs stavudine in combination therapy in antiretroviralnaive patients: 3-year randomized trial. JAMA 2004; 292: 191-201.
158. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-260
159. Martinez E, Larrouse M, Gatell JM. Cardiovascular disease and HIV infection: host, virus, or drugs?. Curr Opinion Infect Dis 2009, 22: 28-34.
160. Mu H, Chai H, Lin PH, et al. Current update on HIV-associated vascular disease and endothelial dysfunction. World J Surg 2007; 31: 632-643 (Pubitemid 46496230)
161. Eugenin EA, Morgello S, Klotman ME, et al. Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIVmediated vascular disease. Am J Pathol 2008; 172: 1100-1111
162. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Inferior clinical outcome of the CD4+ cell countguided antiretroviral treatment interruption strategy in the SMART Study: role of CD4+ cell counts and HIV RNA levels during followup. J Infect Dis 2008; 197: 1145-1155
163. Madden E, Lee G, Kotler DP, et al. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS 2008; 22: 707-715
164. Masiá M, Padilla S, Bernal E, et al. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective crosssectional study in HIV-infected patients. Clin Ther 2007; 29: 1448-1455 (Pubitemid 47354208)
165. D: A: D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multicohort collaboration. Lancet 2008; 371: 1417-1426
166. The SMART/INSIGHT and the D: A: D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22: F17-F24.
167. Goicoechea M, McCutchan A. Abacavir and increased risk of myocardial infarction. Lancet 2008; 372: 803-804
168. Cutrell A, Hernandez J, Brothers C, et al. Is abacavir (ABC)-containing combination antiretroviral therapy (CART) associated with myocardial infarction (MI)? No association identified in pooled summary of 54 clinical trials. XVII International AIDS Conference. Mexico City, August 2008: abstract WEAB0106.
169. Smith KY, Fine D, Patel P, et al. Similarity in efficacy and safety of abacavir/lamivudine compared to tenofovir/emtricitabine in combination with QD lopinavir/ritonavir (LPV/r) over 96 weeks in the HEAT study. XVII International AIDS Conference. Mexico City, August 2008: abstract LBPE1138.
170. French MA, Price P. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18: 1615-1627 (Pubitemid 39095778)
171. Shelburne SA 3rd, Hamill RJ The immune reconstitution inflammatory syndrome. AIDS Rev 2003; 5: 67-69
172. French MA. Disorders of immune reconstitution in patients with HIV infection responding to antiretroviral therapy. Curr HIV/AIDS Rep 2007; 4: 16-21. (Pubitemid 46555247)
173. Lawn SD, Wilkinson RJ. Immune reconstitution disease associated with parasitic infections following antiretroviral treatment. Parasite Immunol 2006; 28: 625-633 (Pubitemid 44581388)
174. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5: 361-373
175. Jenny-Avital ER, Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin Infect Dis 2002; 35: e128-e133.
176. Collazos J, Mayo J, Martinez E, Blanco MS. Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients. AIDS 1999; 13: 1426-1428 (Pubitemid 29408469)
177. Kotecha N, George MJ, Smith TW, Corvi F, Litofsky NS. Enhancing progressive multifocal leukoencephalopathy: an indicator of improved immune status? Am J Med 1998; 105: 541-543
178. Tantisiriwat W, Tebas P, Clifford DB, Powderly WG, Fichtenbaum CJ. Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis 1999; 28: 1152-1154 (Pubitemid 29203555)
179. Komanduri KV, Viswanathan MN, Wieder ED, et al. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998; 4: 953-956
180. Karavellas MP, Lowder CY, Macdonald C, et al.: Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol 1998; 116: 169-175 (Pubitemid 28113316)
181. Deayton JR, Wilson P, Sabin CA, et al. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS 2000; 14: 1163-1170 (Pubitemid 30420659)
182. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80. (Pubitemid 30038386)
183. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006; 57: 167-170 (Pubitemid 43160154)
184. Lawn SD. Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy. Curr Opin Infect Dis 2007; 20: 482-488
185. Cinque P, Pierotti C, Viganò MG, et al. The good and the evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neurovirol 2001; 7: 358-363 (Pubitemid 32894242)
186. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-129 (Pubitemid 34786200)
187. Centers for Disease Control and Prevention. Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/ Infectious Diseases Society of America. MMWR 2004; 53(No.): 1-112.